Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
PURPOSE: Kaposi's sarcoma (KS), the most common neoplasm in patients with AIDS, is a significant clinical problem for which current therapies are frequently unsatisfactory. We conducted a randomized phase III clinical trial to compare the efficacy and toxicities of a new form of therapy, pegylated-liposomal doxorubicin, with standard combination chemotherapy in patients with advanced AIDS-related KS (AIDS-KS). PATIENTS AND METHODS: Two hundred fifty-eight patients with advanced AIDS-KS were randomly assigned to receive either pegylated-liposomal doxorubicin (20 mg/m2) or the combination of doxorubicin (20 mg/m2), bleomycin (10 mg/m2) and vincristine (1 mg) (ABV) every 14 days for six cycles. Standard response criteria, toxicity criteria, and predefined indicators of clinical benefit were examined to evaluate outcomes. RESULTS: Among 133 patients randomized to receive pegylated-liposomal doxorubicin, one achieved a complete clinical response and 60 achieved a partial response for an overall response rate of 45.9% (95% confidence interval [CI], 37% to 54%). Among 125 patients randomized to receive ABV, 31 achieved a partial response (24.8%; 95% confidence interval [CI], 17% to 32%). This difference was statistically significant (P < .001). In addition to objective responses, prospectively defined clinical benefits and toxicity outcomes also favored pegylated-liposomal doxorubicin. CONCLUSION: Pegylated-liposomal doxorubicin is more effective and less toxic than the standard combination chemotherapy regimen ABV for treatment of AIDS-KS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?
Beral, V., Peterman, T. A., Berkelman, R. L., & Jaffe, H. W. (1990) · The Lancet · doi:10.1016/0140-6736(90)90001-l · Cited by 1,056
Krown, S. E., Metroka, C., & Wernz, J. C. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1201 · Cited by 478
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Gabizón, A. (1992) · PubMed · Cited by 421
Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Self-citationStewart, S., Jablonowski, H., Goebel, F. D., Arasteh, K., Spittle, M., Rios, A., Aboulafia, D., Galleshaw, J., & Dezube, B. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.683 · Cited by 358
Self-citationHuang, S. K., Mayhew, E. G., Gilani, S., Lasiç, D. D., Martin, F. J., & Papahadjopoulos, D. (1992) · PubMed · Cited by 274
Gabizon, A. A., Barenholz, Y., & Bialer, M. (1993) · Pharmaceutical Research · doi:10.1023/a:1018907715905 · Cited by 237
Krown, S. E., Metroka, C. E., & Wernz, J. (1989) · Cited by 217
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030
Antman, K., & Chang, Y. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004063421407 · Cited by 1,023
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Lammers, T., Aime, S., Hennink, W. E., Storm, G., & Kiessling, F. (2011) · Accounts of Chemical Research · doi:10.1021/ar200019c · Cited by 870
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Cesarman, E., Damania, B., Krown, S. E., Martin, J., Bower, M., & Whitby, D. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0060-9 · Cited by 697
Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues
Pandita, D., Madaan, K., Kumar, S., Poonia, N., & Lather, V. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.130965 · Cited by 679
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Multifunctional Nanoparticles for Drug Delivery and Molecular Imaging
Bao, G., Mitragotri, S., & Tong, S. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152409 · Cited by 536
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
HIV-Associated Cancers and Related Diseases
Yarchoan, R., & Uldrick, T. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1615896 · Cited by 521
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Nanotheranostics and image-guided drug delivery: current concepts and future directions
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100228v · Cited by 397
Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Red blood cell-mimicking synthetic biomaterial particles
Doshi, N., Zahr, A. S., Bhaskar, S., Lahann, J., & Mitragotri, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907127106 · Cited by 374
Dendrimers: A versatile nanocarrier for drug delivery and targeting
Sherje, A. P., Jadhav, M., Dravyakar, B. R., & Kadam, D. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.030 · Cited by 373
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities
Kashyap, B. K., Singh, V. V., Solanki, M. K., Kumar, A., Ruokolainen, J., & Kesari, K. K. (2023) · ACS Omega · doi:10.1021/acsomega.2c07840 · Cited by 348
Hengge, U. R., Ruzicka, T., Tyring, S. K., Stuschke, M., Roggendorf, M., Schwartz, R. A., & Seeber, S. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00263-3 · Cited by 329
Nanoscale Self-Assembly for Therapeutic Delivery
Yadav, S., Sharma, A. K., & Kumar, P. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00127 · Cited by 324
Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines
Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Artificial exosomes for translational nanomedicine
Li, Y.-J., Wu, J.-Y., Liu, J., Xu, W., Qiu, X., Huang, S., Hu, X.-B., & Xiang, D.-X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00986-2 · Cited by 303
Rafiyath, S. M., Rasul, M., Lee, B., Wei, G., Lamba, G., & Liu, D. (2012) · Experimental Hematology & Oncology · doi:10.1186/2162-3619-1-10 · Cited by 302
Role of anthracyclines in the era of targeted therapy
Cortés-Funes, H., & Coronado, C. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0015-3 · Cited by 294
Supramolecular Nanodevices: From Design Validation to Theranostic Nanomedicine
Cabral, H., Nishiyama, N., & Kataoka, K. (2011) · Accounts of Chemical Research · doi:10.1021/ar200094a · Cited by 292
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., & Kirpotin, D. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21358 · Cited by 289
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Landon, C. D. (2011) · The Open Nanomedicine Journal · doi:10.2174/1875933501103010038 · Cited by 281
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Skubitz, K. M., & D'Adamo, D. R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1409 · Cited by 277
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Sun, D., Zhou, S., & Gao, W. (2020) · ACS Nano · doi:10.1021/acsnano.9b09713 · Cited by 263
Liposomal drug formulations in cancer therapy: 15 years along the road
Slingerland, M., Guchelaar, H.-J., & Gelderblom, H. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.015 · Cited by 250
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Drug delivery approaches for breast cancer
Singh, S., Singh, S., Lillard Jr, J. W., & Singh, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140325 · Cited by 219
“66,67 The water solubility and size of dendrimers increased by PEGylation which helped to improve the retention and biodistribution characteristics.”
Cancer‐Targeted Nanotheranostics: Recent Advances and Perspectives
Ma, Y., Huang, J., Song, S., Chen, H., & Zhang, Z. (2016) · Small · doi:10.1002/smll.201600635 · Cited by 216
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
Dou, Y., Hynynen, K., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.025 · Cited by 210
Polizzotto, M. N., Uldrick, T. S., Hu, D., & Yarchoan, R. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00073 · Cited by 196
“Liposomal doxorubicin has a high affinity for the pathogenic spindle cell in KS lesions, and, when available, is currently the standard of care for first line therapy of KS (Northfelt et al., 1998; Cianfrocca et al., 2010).”
BackgroundKaposi sarcoma herpesvirus-associated cancers and related diseases
Goncalves, P. H., Ziegelbauer, J., Uldrick, T. S., & Yarchoan, R. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000330 · Cited by 174
Lee, J., Kim, J., Jeong, M., Lee, H., Goh, U., Kim, H., Kim, B., & Park, J.-H. (2015) · Nano Letters · doi:10.1021/nl5047494 · Cited by 170
Bhutani, M., Polizzotto, M. N., Uldrick, T. S., & Yarchoan, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.027 · Cited by 155
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Ogawara, K.-I., Un, K., Tanaka, K.-I., Higaki, K., & Kimura, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.008 · Cited by 101
Thinking about Enhanced Permeability and Retention Effect (EPR)
Leporatti, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081259 · Cited by 58
“Therefore, it is not the EPR effect that failed in clinical trials, but rather the PEGylation of liposomal chemo drugs that failed to achieve satisfactory cytotoxicity efficacy within a 48 h period in clinical application [7].”
Background
Metadata
- Authors
- Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-07
- Volume
- 16
- Issue
- 7
- Pages
- 2445-2451
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1918322381
- Cited by
- 649
- References
- 13
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.